Regulatory options for pharmacogenetics

Pharmacogenomics

Volumn 4, Issue 5, 2003, Pages 527-530

  Melzer, David ^a   Zimmern, Ron L ^b   Detmer, Don E ^c,e   Ling, Tom ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Public Health Genetics Unit   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; TRASTUZUMAB;

COMPUTER ANALYSIS; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; GENETIC ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; MEDICAL INFORMATION; PHARMACOGENETICS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; RELIABILITY; RISK ASSESSMENT;

DRUG DESIGN; PHARMACOGENETICS; POLICY MAKING; RESEARCH DESIGN; UNITED STATES;

EID: 0141516711     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.4.5.527.23802     Document Type: Editorial

References (13)

1. Roses AD: Pharmacogenetics. Hum. Mol. Genet. 10, 2261-2267 (2001).
2. Ginsburg GS, McCarthy JJ: Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 19, 491-496 (2001).
3. Wolf CR, Smith G: Pharmacogenetics. Br. Med. Bull. 55, 366-386 (1999).
4. Wennberg JE: Unwarranted variations in healthcare delivery: implications for academic medical centres. Br. Med. J. 325, 961-964 (2002).
5. Burke W, Atkins D, Gwinn M et al.: Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am. J. Epidemiol. 156, 311-318 (2002).
6. O'Kane DJ, Weinshilboum RM, Moyer TP: Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics 4, 1-4 (2003).
7. Holtzman NA, Shapiro D: The new genetics: genetic testing and public policy. Br. Med. J. 316, 852-856 (1998).
8. Melzer D, Raven A, Jillions D, Detmer D, Ling T, Zimmern R: My very own medicine; what must I know? Information policy for pharmacogenetics. Department of Public Health and Primary Care, University of Cambridge (2003).
9. Danzon P, Towse A: The economics of gene therapy and of pharmacogenetics. Value Health 5, 5-13 (2002).
10. Feigal D, Gutman SI: Drug development, regulation and genetically guided therapy. In: Pharmacogenomics: Social, Ethical and Clinical Dimensions. Rothstein M (Ed.), John Wiley & Sons, Inc., Howboken, NJ 99-108 (2003).
11. Higson G: Medical Device Safety: The Regulation of Medical Devices for Public Health and Safety. Inst. Physics Pub. (2002).
12. Directive 98/79/EC on In Vitro Diagnostic Medical Devices (EC98a). Official Journal L331 (1998).
13. Lindpainter K, Foot E, Caulfield M, Hall I: Pharmacogenetics: focus on pharmacodynamics. Intern. J. Pharm. Med. 15, 74-82 (2001).